



<b>Industry:</b>	Medical Device
<b>Management:</b>	<u>Executive Leadership</u> Robert Jacobs, CEO Richard Barakat, CMO Paul Booth, CTO
<b>Number of Employees:</b>	3
<b>Finance:</b>	<u>Financial</u> Full Stack Finance  <u>Funding</u> \$2M - Series A
<b>Legal:</b>	<u>Corporate:</u> Ryan Connor, Esq.  <u>IP:</u> David Fortunato, Esq.

**Executive Summary:**

To address current limitations in the state of hysterectomy procedures, we have developed a novel solution using robotic technologies to enhance surgical control. Our Robotic Surgical Assistant was designed from the ground up to provide more control to surgeons when, where, and how they need it. Our founders authored the underlying intellectual property, while at Memorial Sloan Kettering Cancer Center (MSK), designed to greatly improve the surgical experience from both a surgeon and hospital approach. Applied Surgical Robotics was established to focus on robotic breakthroughs and, through a worldwide exclusive license with our partner MSK, we look forward to bringing our first production device to market in 2022 – the Barakat Automated Uterine Manipulator (BAUM).

**Company History:**

Applied Surgical Robotics, LLC was formed in late 2017 to both license the technology from Memorial Sloan Kettering Cancer Center and to develop and commercialize the technology. We have hired an experienced CEO, and have established ongoing business relationships with development, financial, regulatory, and legal organizations who bring expertise to their respective fields.

**Market Opportunity / Unmet Need:**

There are over 700,000 hysterectomies performed each year in the United States and over 3.5MM globally which represents a \$2.8B potential market. Uterine manipulation is a critical component of a successful minimally invasive hysterectomy, the second most common surgical procedure women undergo in the United States. In the course of performing these procedures the current standard of practice is for a surgical assistant, taking positional instructions from the operating surgeon, to manipulate the anatomy using hand-held tools. This current setup and process is challenging for both surgeon and assistant as the physical demands to the assistant can be significant and the resulting anatomical positioning may not reflect exactly what the surgeon requires.

**Products/Services – Launched & Pipeline:**

The BAUM – Robotic Surgical Assistant is currently in clinical trial at Memorial Sloan Kettering Cancer Center. Design specifications for a Design-For-Manufacture solution have been drafted using the base configuration and lessons learned from the trial. Our seasoned medical device development and regulatory guidance partner, MPR Associates, has identified a 1-year development pathway to complete a design for regulatory submission. Initial availability for sale is anticipated 18 months after initial development.

**Intellectual Property:**

Memorial Sloan Kettering Cancer Center, the host institution for the initial development, has filed non provisional patents including PCT. Applied Surgical Robotics has secured a worldwide exclusive license to the technology.

**Financial Projections (Unaudited):**

		yr1	yr2	yr3	yr4	yr5	yr6
		2021	2022	2023	2024	2025	2026
<b>Revenue</b>							
BAUM		\$ -	\$ 2,450,000	\$ 7,350,000	\$ 17,640,000	\$ 44,590,000	\$ 77,420,000
Consumables		\$ -	\$ 59,520	\$ 570,240	\$ 1,471,360	\$ 4,172,960	\$ 8,961,824
	<i>totals</i>	\$ -	\$ 2,509,520	\$ 7,920,240	\$ 19,111,360	\$ 48,762,960	\$ 86,381,824

**Primary purpose of Presentation:**

Investment